| 한국인 다발성경화증과 임상적단독증후군 환자에서 인터페론 베타 1b의 내약성 |
|
김유환1, 김병조1, 김병준2, 오지영3, 주인수4, 임영민5, 이연정6, 김광국5 |
1고려대학교 의과대학 신경과학교실
2성균관대학교 의과대학 삼성서울병원 신경과학교실
3건국대학교 의학전문대학원 신경과학교실 |
| Tolerability of Interferon Beta-1b for Multiple Sclerosis and Clinically Isolated Syndrome in Korea |
|
YooHwan Kim1, Byung-Jo Kim1, Byoung Joon Kim2, Jeeyoung Oh3, In Soo Joo4, Young-Min Lim5, Yoen Jung Lee6, Kwang-Kuk Kim5 |
1Department of Neurology, Korea University Medical Center
2Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine
3Department of Neurology, Konkuk University School of Medicine, Seoul |
|
|
| Abstract |
|
"Background: Interferon beta-1b has been used for relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) with excellent safety profiles. Although a recent study suggestedno difference in clinical manifestations between Caucasians and Koreans, effective drugdosage and tolerability could be different among patients with different ethnicity. This study was performedto investigate tolerability and any factors affecting tolerability of interferon beta-1b in Koreanpatients with MS or CIS.Methods: All patients who have been injecting interferon beta-1b for MS or CIS were recruited from39 nation-wide university affiliated hospitals in Korea from August 2006 to July 2012. All subjectswere asked to report any adverse events (AEs) after injecting interferon beta 1b using a selfquestionnaire.Results: A total of 355 patients (322 MS and 33 CIS) were enrolled. 96 AEs were reported by 59 patients(16.62%) except injection site reaction. 35 AEs by 23 patients (6.48%) were drug relatedevents listed in drug information. Of 16 serious AEs reported by 9 patients (2.54%), 13 events wererelated to relapse and the other 3 events were 1 suicide attempt and 2 injection site infection. Any injectionsite reactions were reported in 38% of patients, but all events were mild. No one discontinuedinterferon beta-1b during study period.Conclusions: Compared to previous studies, occurrence rate of AEs by interferon beta-1b in Koreanpatients with MS showed similar results. Journal of Multiple Sclerosis 6(2):29-36, 2015" |
| Key Words:
Interferon beta-1b, Relapsing-remitting multiple sclerosis, Clinically isolated syndrome, Tolerability |
|
PDF Links
Download Citation
